Hong Kong-based cross-border healthcare investment firm Ally Bridge Group has completed investments in two European biopharmaceutical companies, Galenica AG of Switzerland and Nabriva of Austria and the U.S., further expanding the firm's global portfolio.
No Financial details were disclosed. These two investments follow Ally Bridge's previously deals privatizing China's WuXi PharmaTech and is investment in Tesaro, Inc., a U.S. oncology-focused biopharmaceutical company, and other global healthcare companies.
Galenica, through its subsidiary Vifor Pharma, provides iron supplements and therapeutics treating chronic kidney disease, a prevalent and steadily growing indication worldwide. The company, based in Bern, Switzerland, is expanding its franchise further into nephrology, and new areas such as cardiology, women's health and gastroenterol...
This news article comes via , who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of China Money Network
